公开(公告)号：US20220289819A1

公开(公告)日：2022-09-15

申请号：US17770500

申请日：2019-11-07

Applicant: GREEN CROSS CORPORATION ,  MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Mi-Young OH ,  Jae-Chul LEE ,  Hye Young PARK ,  Hye In YUM ,  Dong-Sik KIM

IPC: C07K14/705 ,  C07K16/28 ,  A61P35/00

Abstract: A steric epitope of CEACAM1 is disclosed. An anti-CEACAM1 antibody or a fragment thereof, which specifically binds to CEACAM1 is disclosed. A steric epitope of CEACAM1 includes all amino acids in critical positions for specific binding to an anti-CEACAM1 antibody and maintains an appropriate three-dimensional structure, and thus can high affinity for an anti-CEACAM1 antibody. In addition, an antibody, or a fragment thereof, that specifically binds to a steric epitope can effectively suppress CEACAM1-CEACAM1 interaction and CEACAM1-CEACAM6 interaction.

公开(公告)号：US20220135679A1

公开(公告)日：2022-05-05

申请号：US17431218

申请日：2020-04-06

Applicant: GREEN CROSS CORPORATION

Inventor： Jae Chan PARK ,  Eun Jung SONG ,  So Jung LIM ,  Jae-Chul LEE ,  Hae Naem KWON ,  Su A LEE ,  Ok Jae LIM ,  Mun Kyung KIM ,  Hyun Jung CHO ,  Gil-Jung KIM ,  Jee Won LEE ,  Sung Keun KIM ,  Jong Wha WON ,  Shin A JANG

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30

Abstract: A bispecific anti-GPNMB/anti-CD3 antibody specifically binds to CD3 (cluster of differentiation 3) and GPNMB (glycoprotein non-metastatic melanoma protein B) and uses thereof are disclosed. The bispecific antibody shows high affinity and specificity to CD3 and GPNMB and thus can induce death of cancer cells expressing GPNMB and inhibit proliferation thereof. Therefore, the bispecific antibody can be used as an effective therapeutic agent for cancers expressing GPNMB.